Inhibitory effect of liposomal MDP-Lys on lung metastasis of transplantable osteosarcoma in hamster

Oncology Research

Volumn 12, Issue 1, 2000, Pages 25-31

  Nitta, Yasuaki ^a   Sugita, Takashi ^a   Ikuta, Yoshikazu ^a   Murakami, Teruo ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Hamster; Liposome; Lung metastasis; MDP Lys; Osteosarcoma

Indexed keywords

DRUG DERIVATIVE; LIPOSOME; MUROCTASIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

ANIMAL; ARTICLE; BODY WEIGHT; BONE TUMOR; CANCER TRANSPLANTATION; COMPARATIVE STUDY; HAMSTER; LUNG TUMOR; MALE; MESODERM; METASTASIS; OSTEOSARCOMA; PATHOLOGY; SURVIVAL; TIME;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANIMALS; BODY WEIGHT; BONE NEOPLASMS; CRICETINAE; LIPOSOMES; LUNG NEOPLASMS; MALE; MESODERM; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0034567817     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000001108747417     Document Type: Article

References (27)

1. Ogura, T. Bases on timing of combined modality of chemotherapy and immunotherapy. Gan To Kagaku Ryoho 17:1414-1420; 1990.
2. Lederer, E.; Adem, S.; Ciorbar, R. Cell walls of mycobacterium and related organisms: Chemistry and immunostimulant properties. Mol. Cell. Biochem. 7:87-104; 1975.
3. Azuma, I. Synthetic immunoadjuvants: Application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 10:1000-1006; 1992.
4. Azuma, I. Biochemical and immunological properties of the fractions of tubercle bacilli. Kekkaku 73:65-70; 1998.
5. Yoo, Y. C.; Saiki, I.; K. Azuma, I. MDP-Lys, a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumors in mice. Vaccine 12:175-180; 1994.
6. Asano, T.; Fujimaki, W.; McWatters, A.; An, T.; Matsushima, K.; Kleinerman, E. S. Effect of adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol. Immunother. 37:408-411; 1993.
7. Jaffe, N. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: Pre-surgical treatment of primary tumor and of overt plumonary metastases. Cancer 39:45-50; 1977.
8. Fidler, I. J.; Sone, S.; Fogler, W. E. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposome containing muramyl dipeptide. Proc. Natl. Acad. Sci. USA 78:1680-1684; 1981.
9. Sekiguchi, M.; Satomura, T.; Shimada, T. An experimental transplantable osteosarcoma with spontaneous plumonary metastasis in hamsters. Int. J. Exp. Pathol. 75:51-60; 1994.
10. Kotani, S.; Narita, T.; Stewart, D. E. S. Immunoadjuvant activities of cell walls and their water-soluble fractions prepared from various gram-positive bacteria. Biken J. 18:135-138; 1975.
11. Evans, R. Tumor macrophages in host immunity to malignancies. New York: Academic Press; 1976:27-42.
12. Misaki, T.; Watanabe, Y.; Iida, Y. Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol. Immunother. 35:92-96; 1992.
13. Oberling, F. Monocyte/macrophages as effector cells in cancer immunotherapy. Transfus. Sci. 18:243-250; 1997.
14. Lubec, B.; Hoeger, H.; Kremser, K. Decreased tumor incidence and increased survival by one year oral low dose arginine supplementation in the mouse. Life Sci. 58:2317-2325; 1996.
15. MacEwen, E. G.; Kurzman, I. D.; Rosenthal, R. C. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl. Cancer Inst. 81:935-938; 1989.
16. Azuma, I. Review: Inducer of cytokines in vivo: Overview of field and romurtide experience. Int. J. Immunopharmacol. 14:487-496; 1992.
17. Yamaguchi, F.; Akasaki, M.; Tsukada, W. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin. Arzneimittelforschung 38:980-983; 1988.
18. Asano, T.; McWatters, A.; An, T.; Matsushima, K.; Kleinerman, E. S. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J. Pharmacol. Exp. Ther. 268:1032-1039; 1994.
19. Sugawara, T.; Takada, S.; Miyamoto, M.; Nomura, M.; Kato, M. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys (L18) in rat macrophage cultures and dog synovial fluid. Inflammation 20:43-56; 1996.
20. Kleinerman, E. S.; Meyers, P. A.; Jaffe, N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J. Immunother. 17: 181-193; 1995.
21. Schroit, A. J.; Fidler, I. J. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42:161-167; 1982.
22. Link, M. P.; Goorin, A. M.; Miser, A. W. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of extremity. N. Engl. J. Med. 314:1600-1606; 1986.
23. Kleinerman, E. S.; Raymond, A. K.; Bucana, C. D. Unique histological changes in lung metastasis of osteosarcoma patients following therapy with liposomal muramyl tripeptide. Cancer Immunol. Immunother. 34:211-220; 1992.
24. Kleinerman, E. S.; Gano, J. B.; Jaffe, N. Efficacy of liposomal muramyl tripeptide in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. 18:93-99; 1995.
25. Kleinerman, E. S. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Sarcomas Part 2 9:927-938; 1995.
26. Hibbs, J. B. Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J. Natl. Cancer Inst. 53: 1487-1492; 1974.
27. Abra, R. M.; Hunt, C. A.; Lau, D. T. Liposome disposition in vivo. VI: Delivery to the lung. J. Pharm. Sci. 73:203-206; 1984.